ClinicalTrials.gg
CompletedNCT05113940Updated Oct 24, 2024Results posted

A Study of PF-07258669 In Healthy Adult Participants

A Phase 1 interventional study of PF-07258669 and Placebo in Healthy Participants, sponsored by Pfizer. Completed at 1 site in Belgium. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-10-24.

Sponsored by Pfizer · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Part A of this study is to evaluate safety, tolerability, and pharmacokinetics (PK) of PF-07258669 after administration of multiple ascending oral doses to healthy adult participants. Optional cohorts of healthy adult Japanese participants and/or older adult participants may also be evaluated if results in other cohorts support further evaluation. Part B of this study is a 2-period, fixed-sequence, multiple-dose, open-label design to evaluate the effect of PF-07258669 on midazolam PK in healthy adult participants. Part B will be conducted if the results of Part A support further evaluation of PF-07258669.

02

Conditions studied

  • Healthy Participants

Keywords

  • PF-07258669
  • multiple dose
  • melanocortin-4 receptor
  • MC4R
  • healthy participants
  • safety
  • tolerability
  • pharmacokinetics
03

In context

Lead sponsor

Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.

Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. For optional cohort of older adult participants only: Male participants and female participants of non must be 65 to 90 years of age, inclusive, at the time of signing the ICD ( document). Attempts will be made to ensure that the age composition of this cohort (eg, approximately 70% of participants ≥70 years of age) is comparable to that of the anticipated patient population in later clinical studies.
  2. Female participants of nonchildbearing potential and male participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, laboratory tests, and cardiac monitoring.

    For optional cohort of older adult participants only: Participants must be in a stable condition at admission. These participants must be in reasonably good health as determined by the investigator based on a detailed medical history, full physical examination, vital signs assessments, 12-lead (electrocardiogram), and clinical laboratory tests. Participants with mild, chronic, stable disease (eg, controlled hypertension, noninsulin dependent diabetes, osteoarthritis) may be enrolled if deemed medically prudent by the investigator.

  3. Participants who are willing to avoid direct sunlight exposure or any high intensity ultraviolet light exposure from admission to the follow-up contact and to apply sunscreen/lotion with a high sun protection factor and to wear eye protection, as appropriate.
  4. (BMI) of 17.5 to 28.5 kg/m2; and a total body weight >50 kg (110 lb).

    For optional cohort of older adult participants only: BMI of 17.5 to 32.4 kg/m2; and a total body weight >50 kg (110 lbs). Efforts will be made to enroll at least 3 older adult participants with BMI \<25 kg/m2, if feasible.

  5. Japanese participants only: Participants enrolling as Japanese must have 4 biological Japanese grandparents who were born in Japan.

Exclusion criteria

Exclusion Criteria:

  1. Evidence or history of hematological, renal, endocrine (including, but not limited to, thyroid disease, diabetes insipidus), pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric (including, but not limited to, primary polydipsia, obsessive compulsive disorder, anxiety disorder, schizophrenia), neurological (including, but not limited to, seizure disorder, traumatic brain injury), immunodeficiency (including, but not limited to, severe infection that required ICU admission, prolonged hospitalization, or prolonged treatment) or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing), as well as presence of clinical laboratory abnormalities.

    For optional cohort of older adult participants only: Participants with chronic conditions (eg, hypertension) that are controlled by either diet or stable doses of medications may be included. Recent evidence (ie, within previous 6 months) or history of unstable disease or moderate to severe conditions which would, in the investigator's opinion, interfere with the study evaluations or have an impact on the safety of participants.

  2. History of symptomatic orthostatic hypotension or symptomatic bradycardia.
  3. History of eating disorders (eg, anorexia or bulimia nervosa, binge-eating disorder, avoidant/restrictive food intake disorder).
  4. Use of prescription or nonprescription drugs and dietary and herbal supplements within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention.

    For optional cohort of older adult participants only: Participants taking daily prescription or non-prescription medications (that are not moderate or strong cytochrome P450 () inducers or inhibitors) for management of acceptable chronic medical conditions are to be on a stable dose, as defined by no change in dose for the 28 days or 5 half-lives (whichever is longer) before the screening visit.

    1. Use of stable concomitant mediations noted above that are CYP3A substrates may be restricted.
    2. All medications must be reviewed on a case-by-case basis by the investigator and approved by the sponsor during the screening period for eligibility purposes.
  5. Use of moderate or strong cytochrome P450 3A (CYP3A) inhibitors or inducers within 28 days or 5 half-lives (whichever is longer) prior to first dose of study intervention.
  6. Previous administration with an drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
  7. Fasting serum triglycerides >2× (upper limit of normal).
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
120 participants (actual)

Study arms

  • Experimental
    PF-07258669 and Placebo (Cohort 1)

    Dose level 1: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Carbohydrate High Calorie (HCHC)

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 2)

    Dose level 2: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: HCHC

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 3)

    Dose level 3: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: HCHC

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 4)

    Dose level 4: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: Standard Diet (SD)

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 5)

    Dose level 5: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 6)

    Multiple dose administration of PF-07258669 and placebo over 14 days in Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    Midazolam with and without PF-07258669 (Cohort 8)

    Drug-drug interaction assessment of pharmacokinetics interaction in PF-07258669 and midazolam Dietary allocation: SD

    Drug: PF-07258669 · Drug: Midazolam

  • Experimental
    PF-07258669 and Placebo (Cohort 7)

    Multiple dose administration of PF-07258669 and placebo over 14 days in older adult participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 9)

    Dose level 6: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 10)

    Dose level 7: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 11)

    Dose level 8: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: SD

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 12)

    Dose Level 9: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Fat High Calorie (HFHC)

    Drug: PF-07258669 · Drug: Placebo

  • Experimental
    PF-07258669 and Placebo (Cohort 13)

    Dose Level 10: Multiple dose administration of PF-07258669 and placebo over 14 days in non-Japanese participants; 8 participants will receive PF-07258669 and 2 will receive placebo Dietary allocation: High Fat High Calorie (HFHC)

    Drug: PF-07258669 · Drug: Placebo

Interventions

  • PF-07258669 will be administered as tablets; every 8 hour (Q8H) or every 12 hour (Q12H) over 14 days

  • DrugPlacebo

    Placebo will be administered as tablets; Q8H or Q12H over 14 days

  • Single doses of Midazolam will be administered as oral solution alone and in combination with PF-07258669

06

What researchers measure

Primary outcomes

  1. Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events between first dose of study intervention and up to 35 days after last dose of study intervention that were absent before treatment or that worsened after treatment.

    Time frame: Part A: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 49 days)

  2. Part A: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality

    Laboratory assessments included clinical chemistry, hematology, and urinalysis. Abnormality was determined based on the criteria specified in the sponsor reporting standards. The primary criteria was less than (\<) 0.8\* lower limit of normal (LLN) for lymphocytes and lymphocytes/leukocytes, greater than (\>) 1.2\* upper limit of normal (ULN) for lymphocytes, eosinophils/leukocytes, monocytes, and monocytes/leukocytes; greater than (\>) 3.0\* ULN for alanine aminotransferase, \>1.3\* ULN for urea nitrogen, cholesterol, and triglycerides; \>1.030 for specific gravity (scalar), greater than or equal to (\>=) 1 for ketones, urine protein, urine hemoglobin, urine bilirubin, leukocyte esterase.

    Time frame: Part A: Baseline to maximum up to 10 days after administration of the final dose of study intervention (maximum up to 24 days)

  3. Part A: Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data

    Vital signs included: a) supine systolic blood pressure (SBP): change greater than or equal to (\>=) 30 millimeters of mercury (mmHg) increase, postural difference (supine standing) \>= 20 mmHg, standing systolic SBP (mmHg) less than (\<) 90 mmHg, \>= 160 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; b) supine diastolic blood pressure (DBP) \< 50 mmHg, \>= 90 mmHg, change \>= 20 mmHg increase, change \>= 20mmHg decrease; postural difference (supine standing) \>= 10 mmHg; standing \<50 mmHg, value \>=90 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease, C) standing pulse rate (PR) greater than (\>) 140 bpm. Baseline for supine BP and pulse rate was defined as the average of the triplicate measurements collected at the pre-dose (0 hour) assessment on Day 1. Baseline for standing BP, standing pulse rate, respiratory rate and oral body temperature were defined as the pre-dose (0 hour) assessment on Day 1.

    Time frame: Part A: Baseline to maximum up to 10 days after administration of the final dose of study intervention (maximum up to 24 days)

  4. Part A: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria

    ECG criteria: QTc corrected using Fridericia's formula (QTCF) interval aggregate in milliseconds (msec): less than or equal to (\<=) change \<= 60 msec. Baseline was defined as the average of the triplicate ECG measurements over the 3 pre-dose measurement times (-1 hour, -0.5 hour, and pre-dose 0 hour; total of 9 ECG measurements) on Day 1.

    Time frame: Part A: Baseline to maximum up to 10 days after administration of the final dose of study intervention (maximum up to 24 days)

  5. Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Screening

    C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

    Time frame: Part A: At Screening (Day-28 [28 days prior to dosing] to Day -3 [3 days prior to dosing])

  6. Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day -2

    C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

    Time frame: Part A: On Day -2 (2 days prior to dosing)

  7. Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 7

    C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

    Time frame: Part A: On Day 7

  8. Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 14

    C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

    Time frame: Part A: Day 14

  9. Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 21

    C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

    Time frame: Part A: Day 21

  10. Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day at Screening

    All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by clinical research unit (CRU) staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.

    Time frame: Part A: At Screening (Day-28 [28 days prior to dosing] to Day -3 [3 days prior to dosing])

  11. Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day -1

    All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.

    Time frame: Part A: Day -1 (1 day prior to dosing)

  12. Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 7

    All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.

    Time frame: Part A: Day 7

  13. Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 14

    All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.

    Time frame: Part A: Day 14

  14. Part B: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone on Day 1 of Period 1

    Cmax was defined as the maximum observed plasma concentration.

    Time frame: Part B/Period 1: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 1

  15. Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 2 of Period 2

    Cmax is the maximum observed plasma concentration.

    Time frame: Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 2

  16. Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 10 of Period 2

    Cmax was defined as the maximum observed plasma concentration.

    Time frame: Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 10

  17. Part B: Area Under the Plasma Concentration-Time Curve From Time Zero (0) to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam Alone on Day 1 of Period 1

    AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.

    Time frame: Part B/Period 1: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 1

  18. Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 2 of Period 2

    AUClast was defined as the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.

    Time frame: Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 2

  19. Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 10 of Period 2

    AUClast was defined as the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.

    Time frame: Part B/ Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 10

  20. Part B: Area Under the Plasma Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUCinf) of Midazolam Alone on Day 1 of Period 1

    AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.

    Time frame: Part B/Period 1: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 1

  21. Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 2 of Period 2

    AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.

    Time frame: Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 2

  22. Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 10 of Period 2

    AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.

    Time frame: Part B/ Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 10

Secondary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of PF-07258669 on Days 1 and 14

    Cmax was defined as the maximum plasma concentration.

    Time frame: Part A: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose on Day 1 and Day 14

  2. Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax,dn) of PF-07258669 on Days 1 and 14

    Cmax was defined maximum observed serum concentration. Cmax (dn) was calculated as Cmax/dose.

    Time frame: Part A: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose on Day 1 and Day 14

  3. Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to Dosing Interval (Tau) (AUCtau) of PF-07258669 on Days 1 and 14

    Area under the plasma concentration-time profile from time zero to time tau, the dosing interval, where tau = 8 hours.

    Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 1 and Day 14

  4. Part A: Dose Normalized Area Under the Curve From Time 0 to Dosing Interval (Tau) (AUCtau, dn) of PF-07258669 on Days 1 and 14

    Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 1 and Day 14

  5. Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07258669 on Days 1 and 14

    Tmax was defined as the time taken (in hours) to reach the maximum plasma drug concentration.

    Time frame: Part A: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose on Day 1 and Day 14

  6. Part A: Amount of PF-0728669 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)

    Aetau was defined as the amount of unchanged drug recovered in urine during the dosing interval.

    Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 14

  7. Part A: Percentage Dose of PF-07258669 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)

    Aetau% was defined as the percentage of dose recovered in urine as unchanged drug.

    Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 14

  8. Part A: Renal Clearance (CLr) of PF-07258669

    Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).

    Time frame: Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 14

  9. Part B: Number of Participants With TEAEs

    An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment.

    Time frame: Part B: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 46 days)

  10. Part B: Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data

    Vital signs examination included: supine systolic blood pressure with criteria change \>= 30 mmHg decrease, supine diastolic blood pressure with criteria value \>= 90 mmHg and change \>= 20 mmHg decrease.

    Time frame: Part B: Day 1 of Period 1 up to Day 10 of Period 2 (12 days)

  11. Part B: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria

    Following ECG parameters were analyzed: QTCF interval with criteria 450 less than (\<) value less than or equal to (\<=) 480. A standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measures PR, QT, and QTc intervals and QRS complex. On Day 1 at -1 hour (h), -0.5h, and 0h prior to the morning dose, triplicate 12-lead ECGs were obtained approximately 2 to 4 minutes apart at each time point. The average of the triplicate ECG measurements over the 3 pre dose measurement times (total of 9 ECG measurements) collected before morning dose administration on Day 1 served as each participant's baseline QTc value.

    Time frame: Part B: Day 1 of Period 1 up to Day 10 of Period 2 (12 days)

  12. Part B: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality

    Laboratory parameters assessed included: hematology (monocytes, monocytes/leukocytes) with primary criteria greater than (\>) 1.2\*upper limit of normal (ULN), clinical chemistry (bilirubin, direct bilirubin and indirect bilirubin with primary criteria \>1.5\*ULN, alanine aminotransferase with primary criteria \>3.0\*ULN, creatine kinase with primary criteria \>2.0\*ULN, urobilinogen with primary criteria greater than or equal to (\>=)1, cholesterol and triglycerides-fasting with primary criteria \>1.3\*ULN), urinalysis (ketones and urine hemoglobin with primary criteria \>=1).

    Time frame: Part B: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 46 days)

07

Results

Posted Oct 24, 2024
Limitations and caveats
Any untoward findings identified on physical and/or neurological examinations, cardiac monitoring and pulse oximeter monitoring conducted during the active collection period were captured as adverse events, if those findings met the definition of an AE.

Participant flow

This study consisted of two parts: Part A and Part B. A total of 120 participants were enrolled in the study.

Part A (18 Days)
Participant flow — Part A (18 Days)
MilestonePlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)Midazolam Then PF-07258669 + Midazolam: Standard Diet
Started688710888881212150
Completed68769888881210150
Not completed001110000002000
Withdrew: Adverse event001110000002000
Part B- Period 1 (3 Days)
Participant flow — Part B- Period 1 (3 Days)
MilestonePlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)Midazolam Then PF-07258669 + Midazolam: Standard Diet
Started0000000000000011
Completed0000000000000011
Not completed000000000000000
Part B- Period 2 (8 Days)
Participant flow — Part B- Period 2 (8 Days)
MilestonePlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)Midazolam Then PF-07258669 + Midazolam: Standard Diet
Started0000000000000011
Completed000000000000009
Not completed000000000000002
Withdrew: Adverse event000000000000002

Outcome measures

PrimaryPart A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events between first dose of study intervention and up to 35 days after last dose of study intervention that were absent before treatment or that worsened after treatment.

Time frame:
Part A: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 49 days)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With Treatment Emergent Adverse Events (TEAEs)586696747881003
PrimaryPart A: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality

Laboratory assessments included clinical chemistry, hematology, and urinalysis. Abnormality was determined based on the criteria specified in the sponsor reporting standards. The primary criteria was less than (\<) 0.8\* lower limit of normal (LLN) for lymphocytes and lymphocytes/leukocytes, greater than (\>) 1.2\* upper limit of normal (ULN) for lymphocytes, eosinophils/leukocytes, monocytes, and monocytes/leukocytes; greater than (\>) 3.0\* ULN for alanine aminotransferase, \>1.3\* ULN for urea nitrogen, cholesterol, and triglycerides; \>1.030 for specific gravity (scalar), greater than or equal to (\>=) 1 for ketones, urine protein, urine hemoglobin, urine bilirubin, leukocyte esterase.

Time frame:
Part A: Baseline to maximum up to 10 days after administration of the final dose of study intervention (maximum up to 24 days)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality566695878411813
PrimaryPart A: Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data

Vital signs included: a) supine systolic blood pressure (SBP): change greater than or equal to (\>=) 30 millimeters of mercury (mmHg) increase, postural difference (supine standing) \>= 20 mmHg, standing systolic SBP (mmHg) less than (\<) 90 mmHg, \>= 160 mmHg, change \>= 30 mmHg increase, change \>= 30 mmHg decrease; b) supine diastolic blood pressure (DBP) \< 50 mmHg, \>= 90 mmHg, change \>= 20 mmHg increase, change \>= 20mmHg decrease; postural difference (supine standing) \>= 10 mmHg; standing \<50 mmHg, value \>=90 mmHg, change \>=20 mmHg increase, change \>=20 mmHg decrease, C) standing pulse rate (PR) greater than (\>) 140 bpm. Baseline for supine BP and pulse rate was defined as the average of the triplicate measurements collected at the pre-dose (0 hour) assessment on Day 1. Baseline for standing BP, standing pulse rate, respiratory rate and oral body temperature were defined as the pre-dose (0 hour) assessment on Day 1.

Time frame:
Part A: Baseline to maximum up to 10 days after administration of the final dose of study intervention (maximum up to 24 days)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Supine SBP Change >= 30mmHg increase00101000000000
SBP postural difference >=20mmHg00001011000000
Standing SBP Value < 90 mmHg00000001100100
Standing SBP Value >= 160 mmHg00100012001100
Standing SBP Value >= 30 mmHg increase10101011123301
Standing SBP Value >= 30 mmHg decrease00000001000100
Supine DBP Value >= 30 mmHg decrease00000001000100
Supine DBP value < 50 mmHg00000000001000
Supine DBP value >= 90 mmHg01000000000000
Supine DBP change >= 20 mmHg increase01101000000000
Supine DBP change >= 20 mmHg decrease01000000000000
DBP (mmHg) postural difference (supine standing)01000002002000
Standing DBP value < 50 mmHg00000001000000
Standing DBP value >= 90 mmHg24113133103200
Standing DBP change >= 20 mmHg increase10001010102100
Standing diastolic BP change >= 20 mmHg decrease00000102101110
Standing PR >140 bpm00000010000000
PrimaryPart A: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria

ECG criteria: QTc corrected using Fridericia's formula (QTCF) interval aggregate in milliseconds (msec): less than or equal to (\<=) change \<= 60 msec. Baseline was defined as the average of the triplicate ECG measurements over the 3 pre-dose measurement times (-1 hour, -0.5 hour, and pre-dose 0 hour; total of 9 ECG measurements) on Day 1.

Time frame:
Part A: Baseline to maximum up to 10 days after administration of the final dose of study intervention (maximum up to 24 days)
Reported as:
Count of participants · Participants
Part A: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria01000000110100
PrimaryPart A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Screening

C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

Time frame:
Part A: At Screening (Day-28 [28 days prior to dosing] to Day -3 [3 days prior to dosing])
Reported as:
Count of participants · Participants
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Screening
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) at Screening00000100100000
PrimaryPart A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day -2

C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

Time frame:
Part A: On Day -2 (2 days prior to dosing)
Reported as:
Count of participants · Participants
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day -2
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day -200000000000000
PrimaryPart A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 7

C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

Time frame:
Part A: On Day 7
Reported as:
Count of participants · Participants
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 7
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 700000000000000
PrimaryPart A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 14

C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

Time frame:
Part A: Day 14
Reported as:
Count of participants · Participants
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 14
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 1400000000000000
PrimaryPart A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 21

C-SSRS is interview-based rating scale to assess suicidal ideation and behavior. C-SSRS was mapped to Columbia-Classification Algorithm of Suicide Assessment(C-CASA) and suicidal behavior events were scored as follows:1.Completed suicide,2.Suicide attempt,3.Interrupted attempt,4.Aborted attempt,5.Preparatory actions toward imminent suicidal behaviors. Participants with response "Yes" to items 4,5 or behavioral question of C-SSRS were assessed by clinician and had their suicidality managed. Suicidal behaviors were scored as1.Completed suicide response "Yes" on "Completed Suicide",2.Suicide attempt had response "Yes" on "Actual Attempt",3.Interrupted attempt, had response "Yes" on "Interrupted attempt",4.Aborted attempt, had response "Yes" on "Aborted attempt",5.Preparatory actions toward imminent suicidal behaviors, had response "Yes" on "Preparatory Acts or Behavior".Here, number of participants with positive response (response of "yes") to suicidal behavior or ideation were reported.

Time frame:
Part A: Day 21
Reported as:
Count of participants · Participants
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 21
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With Positive Response on Columbia Suicide Severity Rating Scale (C-SSRS) on Day 2100000000000000
PrimaryPart A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day at Screening

All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by clinical research unit (CRU) staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.

Time frame:
Part A: At Screening (Day-28 [28 days prior to dosing] to Day -3 [3 days prior to dosing])
Reported as:
Count of participants · Participants
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day at Screening
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day at Screening00000000000000
PrimaryPart A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day -1

All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.

Time frame:
Part A: Day -1 (1 day prior to dosing)
Reported as:
Count of participants · Participants
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day -1
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day -100000000000000
PrimaryPart A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 7

All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.

Time frame:
Part A: Day 7
Reported as:
Count of participants · Participants
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 7
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 700000000000000
PrimaryPart A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 14

All fluids consumed by the participants between 0 to 24 hours on days requiring 24-hour fluid intake assessments were recorded by CRU staff. The cumulative fluid intake for the 24-hour period was measured and recorded. Participants were instructed to void urine to empty their bladder at 0 hours. All urine voided after this time was collected up to, and including, a final void of urine at 24 hours.

Time frame:
Part A: Day 14
Reported as:
Count of participants · Participants
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 14
ParticipantsPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Number of Participants With 24-Hour Fluid Intake and Urine Output >6 Liters Per Day on Day 1400000000000000
PrimaryPart B: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone on Day 1 of Period 1

Cmax was defined as the maximum observed plasma concentration.

Time frame:
Part B/Period 1: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 1
Reported as:
Geometric mean · Nanogram per milliliter
Part B: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone on Day 1 of Period 1
Nanogram per milliliterPart B Period 1: Midazolam
Part B: Maximum Observed Plasma Concentration (Cmax) of Midazolam Alone on Day 1 of Period 16.213 ± 43
PrimaryPart B: Cmax of Midazolam in Combination With PF-07258669 on Day 2 of Period 2

Cmax is the maximum observed plasma concentration.

Time frame:
Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 2
Reported as:
Geometric mean · Nanogram per milliliter
Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 2 of Period 2
Nanogram per milliliterPart B Period 2: PF-07258669 + Midazolam (Day 2)
Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 2 of Period 210.83 ± 27
PrimaryPart B: Cmax of Midazolam in Combination With PF-07258669 on Day 10 of Period 2

Cmax was defined as the maximum observed plasma concentration.

Time frame:
Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 10
Reported as:
Geometric mean · Nanogram per milliliter
Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 10 of Period 2
Nanogram per milliliterPart B Period 2: PF-07258669 + Midazolam (Day 10)
Part B: Cmax of Midazolam in Combination With PF-07258669 on Day 10 of Period 211.73 ± 30
PrimaryPart B: Area Under the Plasma Concentration-Time Curve From Time Zero (0) to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam Alone on Day 1 of Period 1

AUClast was the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.

Time frame:
Part B/Period 1: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 1
Reported as:
Geometric mean · Nanogram*hour per milliliter
Part B: Area Under the Plasma Concentration-Time Curve From Time Zero (0) to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam Alone on Day 1 of Period 1
Nanogram*hour per milliliterPart B Period 1: Midazolam
Part B: Area Under the Plasma Concentration-Time Curve From Time Zero (0) to the Time of the Last Quantifiable Concentration (AUClast) of Midazolam Alone on Day 1 of Period 118.56 ± 47
PrimaryPart B: AUClast of Midazolam in Combination With PF-07258669 on Day 2 of Period 2

AUClast was defined as the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.

Time frame:
Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 2
Reported as:
Geometric mean · Nanogram*hour per milliliter
Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 2 of Period 2
Nanogram*hour per milliliterPart B Period 2: PF-07258669 + Midazolam (Day 2)
Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 2 of Period 230.27 ± 35
PrimaryPart B: AUClast of Midazolam in Combination With PF-07258669 on Day 10 of Period 2

AUClast was defined as the area under the plasma concentration-time profile from time 0 to the time of the last quantifiable concentration.

Time frame:
Part B/ Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 10
Reported as:
Geometric mean · Nanogram*hour per milliliter
Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 10 of Period 2
Nanogram*hour per milliliterPart B Period 2: PF-07258669 + Midazolam (Day 10)
Part B: AUClast of Midazolam in Combination With PF-07258669 on Day 10 of Period 240.41 ± 33
PrimaryPart B: Area Under the Plasma Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUCinf) of Midazolam Alone on Day 1 of Period 1

AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.

Time frame:
Part B/Period 1: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 1
Reported as:
Geometric mean · Nanogram*hour per milliliter
Part B: Area Under the Plasma Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUCinf) of Midazolam Alone on Day 1 of Period 1
Nanogram*hour per milliliterPart B Period 1: Midazolam
Part B: Area Under the Plasma Concentration-Time Curve From Time 0 to Extrapolated Infinite Time (AUCinf) of Midazolam Alone on Day 1 of Period 119.35 ± 48
PrimaryPart B: AUCinf of Midazolam in Combination With PF-07258669 on Day 2 of Period 2

AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.

Time frame:
Part B/Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 2
Reported as:
Geometric mean · Nanogram*hour per milliliter
Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 2 of Period 2
Nanogram*hour per milliliterPart B Period 2: PF-07258669 + Midazolam (Day 2)
Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 2 of Period 232.84 ± 32
PrimaryPart B: AUCinf of Midazolam in Combination With PF-07258669 on Day 10 of Period 2

AUCinf was defined as the area under the plasma concentration time profile from time 0 extrapolated to infinite time.

Time frame:
Part B/ Period 2: 0.5, 1, 2, 3, 4, 6, 8, 10, 12, and 16 hours post-dose on Day 10
Reported as:
Geometric mean · Nanogram*hour per milliliter
Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 10 of Period 2
Nanogram*hour per milliliterPart B Period 2: PF-07258669 + Midazolam (Day 10)
Part B: AUCinf of Midazolam in Combination With PF-07258669 on Day 10 of Period 241.16 ± 34
SecondaryPart A: Maximum Observed Plasma Concentration (Cmax) of PF-07258669 on Days 1 and 14

Cmax was defined as the maximum plasma concentration.

Time frame:
Part A: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose on Day 1 and Day 14
Reported as:
Geometric mean · Nanogram per milliliter
Part A: Maximum Observed Plasma Concentration (Cmax) of PF-07258669 on Days 1 and 14
Nanogram per milliliterPF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Day 119.47 ± 2525.06 ± 2250.41 ± 2245.99 ± 47131.2 ± 32468.3 ± 27987.2 ± 281263 ± 371218 ± 421210 ± 9
Day 1421.96 ± 2127.91 ± 2559.76 ± 2957.08 ± 39165.2 ± 25568.5 ± 261246 ± 251464 ± 211772 ± 191750 ± 26
SecondaryPart A: Dose Normalized Maximum Observed Plasma Concentration (Cmax,dn) of PF-07258669 on Days 1 and 14

Cmax was defined maximum observed serum concentration. Cmax (dn) was calculated as Cmax/dose.

Time frame:
Part A: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose on Day 1 and Day 14
Reported as:
Geometric mean · Nanograms per milliliter per milligram
Part A: Dose Normalized Maximum Observed Plasma Concentration (Cmax,dn) of PF-07258669 on Days 1 and 14
Nanograms per milliliter per milligramPF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Day 19.742 ± 258.352 ± 228.403 ± 227.666 ± 476.562 ± 327.803 ± 277.899 ± 287.013 ± 376.770 ± 426.719 ± 9
Day 1410.99 ± 229.301 ± 259.952 ± 299.515 ± 398.269 ± 259.473 ± 269.982 ± 258.134 ± 229.849 ± 199.723 ± 26
SecondaryPart A: Area Under the Plasma Concentration-Time Curve From Time 0 to Dosing Interval (Tau) (AUCtau) of PF-07258669 on Days 1 and 14

Area under the plasma concentration-time profile from time zero to time tau, the dosing interval, where tau = 8 hours.

Time frame:
Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 1 and Day 14
Reported as:
Geometric mean · Nanograms*hours per (/) milliliter
Part A: Area Under the Plasma Concentration-Time Curve From Time 0 to Dosing Interval (Tau) (AUCtau) of PF-07258669 on Days 1 and 14
Nanograms*hours per (/) milliliterPF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Day 146.27 ± 2660.42 ± 27113.6 ± 15107.2 ± 42388.1 ± 381207 ± 262597 ± 293357 ± 343361 ± 273331 ± 13
Day 1462.40 ± 3276.25 ± 30162.0 ± 28147.0 ± 45480.4 ± 281795 ± 263946 ± 285313 ± 315845 ± 196074 ± 21
SecondaryPart A: Dose Normalized Area Under the Curve From Time 0 to Dosing Interval (Tau) (AUCtau, dn) of PF-07258669 on Days 1 and 14
Time frame:
Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 1 and Day 14
Reported as:
Geometric mean · Nanograms*hours/ milliliter/ milligrams
Part A: Dose Normalized Area Under the Curve From Time 0 to Dosing Interval (Tau) (AUCtau, dn) of PF-07258669 on Days 1 and 14
Nanograms*hours/ milliliter/ milligramsPF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Day 123.16 ± 2620.15 ± 2718.93 ± 1517.87 ± 4219.42 ± 3820.14 ± 2620.75 ± 2918.64 ± 3418.67 ± 2718.52 ± 13
Day 1431.21 ± 3225.44 ± 3027.01 ± 2824.47 ± 4524.04 ± 2829.90 ± 2631.57 ± 2829.49 ± 3132.49 ± 1933.74 ± 21
SecondaryPart A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07258669 on Days 1 and 14

Tmax was defined as the time taken (in hours) to reach the maximum plasma drug concentration.

Time frame:
Part A: 0, 0.25, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24 hours post dose on Day 1 and Day 14
Reported as:
Median · Hours
Part A: Time to Reach Maximum Observed Plasma Concentration (Tmax) of PF-07258669 on Days 1 and 14
HoursPF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Day 11.000 (0.500 to 1.50)1.000 (0.500 to 1.05)0.5830 (0.500 to 1.50)0.8265 (0.500 to 1.13)1.010 (0.500 to 2.00)1.000 (0.500 to 1.50)1.000 (0.500 to 1.50)1.000 (1.00 to 1.05)1.000 (0.550 to 1.50)0.5830 (0.500 to 1.50)
Day 141.010 (0.500 to 1.52)1.000 (0.500 to 1.02)0.7415 (0.500 to 1.50)0.7665 (0.500 to 1.07)1.000 (1.00 to 1.53)1.000 (0.500 to 1.05)1.000 (0.500 to 1.08)1.500 (1.00 to 2.00)1.000 (0.500 to 1.50)1.000 (1.00 to 1.02)
SecondaryPart A: Amount of PF-0728669 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)

Aetau was defined as the amount of unchanged drug recovered in urine during the dosing interval.

Time frame:
Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 14
Reported as:
Geometric mean · Milligrams
Part A: Amount of PF-0728669 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)
MilligramsPF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Amount of PF-0728669 Excreted Unchanged in Urine Over the Dosing Interval Tau (Aetau)0.004304 ± 450.004490 ± 1530.01690 ± 340.01462 ± 490.04039 ± 700.1440 ± 430.3173 ± 1090.3371 ± 1880.3146 ± 3140.6581 ± 37
SecondaryPart A: Percentage Dose of PF-07258669 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)

Aetau% was defined as the percentage of dose recovered in urine as unchanged drug.

Time frame:
Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 14
Reported as:
Geometric mean · Percentage of dose
Part A: Percentage Dose of PF-07258669 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)
Percentage of dosePF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Percentage Dose of PF-07258669 Excreted Unchanged in the Urine Over the Dosing Interval Tau (Aetau%)0.2152 ± 450.1496 ± 1530.2814 ± 340.2436 ± 490.2020 ± 700.2400 ± 430.2536 ± 1090.1872 ± 1890.1748 ± 3140.3654 ± 37
SecondaryPart A: Renal Clearance (CLr) of PF-07258669

Renal clearance was calculated as cumulative amount of drug recovered unchanged in urine during the dosing interval (Aetau) divided by area under the plasma concentration time-curve from time zero to end of dosing interval (AUCtau).

Time frame:
Part A: 0 to 8, 8 to 16, and 16 to 24 hours post dose on Day 14
Reported as:
Geometric mean · Liter/ hour
Part A: Renal Clearance (CLr) of PF-07258669
Liter/ hourPF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)
Part A: Renal Clearance (CLr) of PF-072586690.06896 ± 370.05887 ± 1710.1042 ± 440.09946 ± 330.08412 ± 480.08026 ± 550.08040 ± 1160.06341 ± 2410.05381 ± 3500.1083 ± 31
SecondaryPart B: Number of Participants With TEAEs

An AE was any untoward medical occurrence in a participant or clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment.

Time frame:
Part B: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 46 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With TEAEs
ParticipantsPart B Period 1: MidazolamPart B Period 2: PF-07258669 + Midazolam (Day 2)Part B Period 2: PF-07258669 + Midazolam (Day 10)
Part B: Number of Participants With TEAEs282
SecondaryPart B: Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data

Vital signs examination included: supine systolic blood pressure with criteria change \>= 30 mmHg decrease, supine diastolic blood pressure with criteria value \>= 90 mmHg and change \>= 20 mmHg decrease.

Time frame:
Part B: Day 1 of Period 1 up to Day 10 of Period 2 (12 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Categorical Summary of Post-Baseline Vital Signs Data
ParticipantsPart B Period 1: MidazolamPart B Period 2: PF-07258669 + Midazolam (Day 2)Part B Period 2: PF-07258669 + Midazolam (Day 10)
Standing systolic blood pressure011
Standing diastolic blood pressure: value >= 90 mmHg011
Standing diastolic blood pressure: value change >= 20 mmHg decrease021
SecondaryPart B: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria

Following ECG parameters were analyzed: QTCF interval with criteria 450 less than (\<) value less than or equal to (\<=) 480. A standard 12-lead ECGs utilizing limb leads were collected using an ECG machine that automatically calculated the heart rate and measures PR, QT, and QTc intervals and QRS complex. On Day 1 at -1 hour (h), -0.5h, and 0h prior to the morning dose, triplicate 12-lead ECGs were obtained approximately 2 to 4 minutes apart at each time point. The average of the triplicate ECG measurements over the 3 pre dose measurement times (total of 9 ECG measurements) collected before morning dose administration on Day 1 served as each participant's baseline QTc value.

Time frame:
Part B: Day 1 of Period 1 up to Day 10 of Period 2 (12 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria
ParticipantsPart B Period 1: MidazolamPart B Period 2: PF-07258669 + Midazolam (Day 2)Part B Period 2: PF-07258669 + Midazolam (Day 10)
Part B: Number of Participants Who Met Defined Electrocardiogram (ECG) Criteria001
SecondaryPart B: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality

Laboratory parameters assessed included: hematology (monocytes, monocytes/leukocytes) with primary criteria greater than (\>) 1.2\*upper limit of normal (ULN), clinical chemistry (bilirubin, direct bilirubin and indirect bilirubin with primary criteria \>1.5\*ULN, alanine aminotransferase with primary criteria \>3.0\*ULN, creatine kinase with primary criteria \>2.0\*ULN, urobilinogen with primary criteria greater than or equal to (\>=)1, cholesterol and triglycerides-fasting with primary criteria \>1.3\*ULN), urinalysis (ketones and urine hemoglobin with primary criteria \>=1).

Time frame:
Part B: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 46 days)
Reported as:
Count of participants · Participants
Part B: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality
ParticipantsPart B Period 1: MidazolamPart B Period 2: PF-07258669 + Midazolam (Day 2)Part B Period 2: PF-07258669 + Midazolam (Day 10)
Part B: Number of Participants With Laboratory Test Abnormalities Without Regard to Baseline Abnormality244

Adverse events

Collected over Part A: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 49 days), Part B: Day 1 to maximum up to 35 days after administration of the final dose of study intervention (maximum up to 46 days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo: 18-60 Years (HC-HC Diet)0/6 (0%)0/6 (0%)5/6 (83.3%)
PF-07258669 2 mg: 18-60 Years (HC-HC Diet)0/8 (0%)0/8 (0%)8/8 (100%)
PF-07258669 3 mg: 18-60 Years (HC-HC Diet)0/8 (0%)1/8 (12.5%)6/8 (75%)
PF-07258669 6 mg: 18-60 Years (HC-HC Diet)0/7 (0%)0/7 (0%)6/7 (85.7%)
Placebo: 18-60 Years (Standard Diet)0/10 (0%)0/10 (0%)9/10 (90%)
PF-07258669 6 mg: 18-60 Years (Standard Diet)0/8 (0%)0/8 (0%)6/8 (75%)
PF-07258669 20 mg: 18-60 Years (Standard Diet)0/8 (0%)0/8 (0%)7/8 (87.5%)
PF-07258669 60 mg: 18-60 Years (Standard Diet)0/8 (0%)0/8 (0%)4/8 (50%)
PF-07258669 125 mg: 18-60 Years (Standard Diet)0/8 (0%)0/8 (0%)7/8 (87.5%)
PF-07258669 180 mg: 18-60 Years (Standard Diet)0/8 (0%)0/8 (0%)8/8 (100%)
Placebo: 18-60 Years (HF-HC Diet)0/12 (0%)0/12 (0%)8/12 (66.7%)
PF-07258669 180 mg: 18-60 Years (HF-HC Diet)0/12 (0%)0/12 (0%)10/12 (83.3%)
Placebo: Japanese 18-60 Years (Standard Diet)0/1 (0%)0/1 (0%)0/1 (0%)
PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)0/5 (0%)0/5 (0%)3/5 (60%)
Part B Period 1: Midazolam0/11 (0%)0/11 (0%)2/11 (18.2%)
Part B Period 2: PF-07258669 + Midazolam (Day 2)0/11 (0%)0/11 (0%)8/11 (72.7%)
Part B Period 2: PF-07258669 + Midazolam (Day 10)0/9 (0%)0/9 (0%)2/9 (22.2%)
Most frequent serious events
Most frequent serious events
EventPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)Part B Period 1: MidazolamPart B Period 2: PF-07258669 + Midazolam (Day 2)Part B Period 2: PF-07258669 + Midazolam (Day 10)
Neurological symptomNervous system disorders0/60/81/80/70/100/80/80/80/80/80/120/120/10/50/110/110/9
Most frequent other events
Showing 10 of 109
Most frequent other events
EventPlacebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)Part B Period 1: MidazolamPart B Period 2: PF-07258669 + Midazolam (Day 2)Part B Period 2: PF-07258669 + Midazolam (Day 10)
FatigueGeneral disorders3/63/80/80/70/101/80/81/81/81/80/121/120/10/50/110/110/9
HungerGeneral disorders0/60/80/80/71/100/81/84/80/80/80/120/120/10/50/112/110/9
Dry skinSkin and subcutaneous tissue disorders0/61/80/80/72/101/80/80/84/80/81/123/120/10/50/110/110/9
DiarrhoeaGastrointestinal disorders1/60/80/80/71/103/80/80/80/81/80/120/120/10/50/110/110/9
InsomniaPsychiatric disorders0/60/80/80/70/100/80/80/80/83/80/121/120/10/51/110/110/9
NauseaGastrointestinal disorders2/60/80/81/70/100/80/80/80/80/81/120/120/10/50/110/110/9
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders2/61/80/80/70/100/80/80/80/80/80/120/120/10/50/110/110/9
Application site irritationGeneral disorders0/61/80/82/70/100/81/80/80/80/80/120/120/10/50/110/110/9
Dry mouthGastrointestinal disorders0/60/80/80/71/100/80/82/80/80/80/120/120/10/50/110/110/9
DyspepsiaGastrointestinal disorders1/60/80/80/70/100/80/80/80/82/80/121/120/10/50/110/110/9

Baseline characteristics

Safety analysis set included all participants who were randomly assigned to study intervention and who took at least 1 dose of study intervention, for the given part of the study (Part A or B).

Age, Customized
Age, Customized(Participants)Placebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)Midazolam Then PF-07258669 + Midazolam: Standard DietTotal
18-44 Years2776765567101005992
45-64 Years41113233212200227
Not disclosed0000000000001001
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Placebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)Midazolam Then PF-07258669 + Midazolam: Standard DietTotal
Female0000000010000001
Male6887108887812120511118
Not disclosed0000000000001001
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Placebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)Midazolam Then PF-07258669 + Midazolam: Standard DietTotal
Hispanic or Latino0111000130000018
Not Hispanic or Latino6776108875811120510110
Unknown or Not Reported0000000000101002
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Placebo: 18-60 Years (HC-HC Diet)PF-07258669 2 mg: 18-60 Years (HC-HC Diet)PF-07258669 3 mg: 18-60 Years (HC-HC Diet)PF-07258669 6 mg: 18-60 Years (HC-HC Diet)Placebo: 18-60 Years (Standard Diet)PF-07258669 6 mg: 18-60 Years (Standard Diet)PF-07258669 20 mg: 18-60 Years (Standard Diet)PF-07258669 60 mg: 18-60 Years (Standard Diet)PF-07258669 125 mg: 18-60 Years (Standard Diet)PF-07258669 180 mg: 18-60 Years (Standard Diet)Placebo: 18-60 Years (HF-HC Diet)PF-07258669 180 mg: 18-60 Years (HF-HC Diet)Placebo: Japanese 18-60 Years (Standard Diet)PF-07258669 180 mg: Japanese 18-60 Years (Standard Diet)Midazolam Then PF-07258669 + Midazolam: Standard DietTotal
American Indian or Alaska Native0000000000000000
Asian01000010102005010
Native Hawaiian or Other Pacific Islander0000000000000000
Black or African American01013010013100112
White6686786877711001097
More than one race0000000000000000
Unknown or Not Reported0000000000001001
08

Study locations

1 site
  • Pfizer Clinical Research Unit - Brussels
    Brussels, Bruxelles-capitale, Région DE B-1070, Belgium
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Nov 2021 to primary completion in Jul 2023, 20 months.

Results were first posted in Oct 2024, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2021
First posted
Nov 9, 2021
StartActual
Nov 8, 2021
Primary completionActual
Jul 27, 2023
CompletionActual
Jul 27, 2023
Results first posted
Oct 24, 2024
Last update
Oct 24, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 24, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05113940
Lead sponsor
Pfizer
Responsible party
Sponsor
First posted
Nov 9, 2021
Start date
Nov 8, 2021
Primary completion
Jul 27, 2023
Completion
Jul 27, 2023
Results posted
Oct 24, 2024
Last update
Oct 24, 2024

Study contacts

Pfizer CT.gov Call Center
study director · Pfizer

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PF-07258669

Start the discussion